Novartis
Carbon footprint
Primary Climate Goal
Novartis aims to achieve carbon neutrality for Scope 1 + 2 by 2025
Secondary Climate Goal
Novartis aims to achieve net zero for all Scopes by 2040
GHG emissions and Carbon intensity
Novartis reported gross GHG emissions (Scope 1 + 2 before carbon offsets) for the twelve months ending 31 December 2022 at 502 Kt (-143 /-22.2% y-o-y). Also positively, carbon intensity declined to 12 t (-2.1 /-14.7% y-o-y).
Novartis's Scope 3 emissions took off to 8,770 Kt (
The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2025, which translates into the estimated reduction of -167 Kt per annum over the period of FY2023 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Also, the company commits to achieving net zero for all Scopes by 2040, which translates into the estimated reduction of -515 Kt per annum over the period of FY2023 - FY2040. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Novartis aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2025. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.
Novartis also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Swiss multinational pharmaceutical company Novartis commits to reduce absolute scope 1, 2 and 3 GHG emissions 35% by 2030 from a 2016 base-year.